Nautilus gets funding to support migraine drug launch

New Jersey's Nautilus Neurosciences has received an undisclosed investment from Galen Partners to support commercialization of its migraine treatment Cambia, which is set to launch in the first half of this year. The company was founded in November 2009 and with the help of funding from Tailwind Capital. Nautilus also has a second drug candidate--PRO-571 for acute pain--in clinical trials.

"Over the past six months we have raised approximately $25 million," says James Fares, chairman and CEO Nautilus Neurosciences. "With the backing of Tailwind, Galen, and our management team, we are confident that Nautilus is poised to become a leading neurology-focused specialty pharmaceutical company."

- here's the release on Nautilus' round

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.